{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-015844","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.605448+00:00","generated_at":"2026-06-21T12:05:28.910381+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zivo Bioscience receives Nasdaq delisting notice for insufficient equity","bullets":["Nasdaq notified Zivo on Nov 22, 2022 of non-compliance with minimum $2.5M stockholders' equity requirement.","Equity fell below threshold as of Sept 30, 2022; alternative compliance standards also not met.","Company has 45 days (until Jan 6, 2023) to submit a plan to regain compliance; possible 180-day extension.","No immediate impact on trading; common stock (ZIVO) and warrants (ZIVOW) continue trading on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-015844","json":"https://secwatch.observer/filing/0001654954-22-015844.json","markdown":"https://secwatch.observer/filing/0001654954-22-015844.md","text":"https://secwatch.observer/filing/0001654954-22-015844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422015844/0001654954-22-015844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422015844/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:05:28.910381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9035603a8ab775f059fed3da5cb3a72febf5573c","claim":"Zivo Bioscience, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"November 22, 2022, Zivo Bioscience, Inc. (the “Company”) received written notice from the Nasdaq Stock Market (“ Nasdaq ”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders' equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards. Under applicabl","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495422015844/0001654954-22-015844-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}